Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01215149 · ClinicalTrials.gov registry record · Phase 1
Safety and Immunogenicity Study of Ad26-ENVA and Ad35-ENV HIV Vaccines in Healthy HIV-uninfected Adults
A Phase 1 study, sponsored by International AIDS Vaccine Initiative.
- Completed
- Registry status
- Phase 1
- Development phase
- 218
- Enrollment target
NCT01215149 is a Phase 1 study that has completed, run by International AIDS Vaccine Initiative. The registered enrollment target is 218 participants.
The verdict
NCT01215149, a Phase 1 study, has completed, sponsored by International AIDS Vaccine Initiative.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 218 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of Ad26.ENVA.01 and Ad35-ENV in low-risk for HIV-uninfected healthy adults administered in heterologous and homologous prime-boost regimens at different time intervals.
Interventions
- BIOLOGICAL Placebo Control
- BIOLOGICAL Ad35-ENV vaccine
- BIOLOGICAL Ad26.ENVA.01 vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 218 participants |
| Start Date | 2010-10 |
| Est. Completion | 2012-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01215149
The ClinicalTrials.gov registry entry for NCT01215149 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 218 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is International AIDS Vaccine Initiative, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo Control is the first listed.
NCT01215149 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01215149 about?
NCT01215149 is a clinical study titled "Safety and Immunogenicity Study of Ad26-ENVA and Ad35-ENV HIV Vaccines in Healthy HIV-uninfected Adults". The purpose of this study is to evaluate the safety and tolerability of Ad26.ENVA.01 and Ad35-ENV in low-risk for HIV-uninfected healthy adults administered in heterologous and homologous prime-boost regimens at different time intervals.
What is the current status of trial NCT01215149?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 218 participants. The study started on 2010-10. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01215149?
The interventions under investigation include: Placebo Control (BIOLOGICAL), Ad35-ENV vaccine (BIOLOGICAL), Ad26.ENVA.01 vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01215149?
This trial is sponsored by International AIDS Vaccine Initiative, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.